SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 10-K
                  Annual Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

FOR THE FISCAL YEAR ENDED                                 COMMISSION FILE NUMBER
    December 31, 2003                                             0-12248

                                Daxor Corporation
             (Exact name of Registrant as specified in its charter)

           New York                                              13-2682108
(State or other jurisdiction of                                (IRS Employer
incorporation or organization)                            Identification Number)

                                350 Fifth Avenue
                                   Suite 7120
                            New York, New York 10118
               (Address of principal executive offices) (Zip Code)

                  Registrant's telephone number: (212) 244-0555

           Securities registered pursuant to Section 12(b) of the Act:
                          Common Shares, $.01 par value
                                (Title of Class)

        Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether Registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months and (2) has been subject to such filing requirements for
the past 90 days.

                           Yes |X|             No |_|

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-X is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
form 10-K. |_|

As of June 30, 2003, the aggregate market value of the voting stock held by
non-affiliates of the Registrant was $22,532,281. The market value of Common
Stock of the Registrant, par value $.01 per share, was computed by reference to
the closing price of one share on such date, as reported by the American Stock
Exchange, which was $15.60.

The number of shares outstanding of the Registrant's Common Stock, par value
$.01 per share, as of April 11, 2005: 4,637,326 shares.

                      DOCUMENTS INCORPARATED BY REFERENCE:

The information required by Part III is incorporated by reference from the proxy
statement for the 2004 Annual Meeting of Shareholders which will be filed with
the Securities and Exchange Commission within 120 days after the close of the
Registrant's 2003 year end.

<PAGE>

                                DAXOR CORPORATION
                                    FORM 10-K
                   For the Fiscal Year Ended December 31, 2003

                                TABLE OF CONTENTS

Item                               Description                              Page
----                               -----------                              ----

                                     PART I

Item 1. Business                                                               2
Item 2. Properties                                                            11
Item 3. Legal Proceedings                                                     11
Item 4. Submission of Matters to a Vote of Security Holders                   12

                                     PART II

Item 5. Market for Registrant's Common Equity and Related Shareholder
        Matters                                                               12
Item 6. Selected Financial Data                                               13
Item 7. Management's Discussion and Analysis of Financial Condition and
        Results of Operations                                                 14
Item 7A.Quantitative and Qualitative Disclosures about Market Risk            16
Item 8. Consolidated Financial Statements                                     16

        Index to Financial Statements and Schedules                           17
Item 9. Changes and Disagreements with Accountants on Accounting
        and Financial Disclosure                                              18
Item 9A.Controls and Procedures                                               18

                                    PART III

Item 10.Directors and Executive Officers of the Registrant                    18
Item 11.Executive Compensation                                                18
Item 12.Security Ownership of Certain Beneficial Owners and Management
        Related Shareholder Matters                                           18
Item 13.Certain Relationships and Related Transactions                        18
Item 14.Principal Accountant Fees and Services                                18

                                     PART IV

Item 15.Exhibits, Financial Statement Schedule and Reports on Form 8-K        19
        Signatures                                                            20

Exhibit 31.1      Certification of Chief Executive Officer Pursuant to Rule
                  13a-14 of the Exchange Act, as Adopted Pursuant to Section 302
                  of the Sarbanes-Oxley Act of 2002

Exhibit 31.2      Certification of Chief Financial Officer Pursuant to Rule
                  13a-14 of the Exchange Act, as adopted Pursuant to Section 302
                  of the Sarbanes-Oxley Act of 2002

Exhibit 32.1      Certification of Chief Executive Officer Pursuant to 18
                  U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
                  Sarbanes-Oxley Act of 2002.

Exhibit 32.2      Certification of Chief Financial Officer Pursuant to 18
                  U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
                  Sarbanes-Oxley Act of 2002.


                                       1
<PAGE>

Item 1. Business

Daxor Corporation is a medical device manufacturing Company with additional
biotech services. Daxor was originally founded in 1970 for cryobanking services.
For the past 10 years, its major focus has been on the development of an
instrument that rapidly and accurately measures human blood volume. The
instrument, called the BVA-100(TM), is used in conjunction with a single use
diagnostic injection and collection kit. The Company maintains a website,
www.daxor.com which describes its operations.

The Company obtained marketing clearance from the FDA for the instrument and for
its specialized single use injection kit known as Volumex(TM). After successful
beta testing for the Blood Volume Analyzer at hospitals in the New York
metropolitan region, the Company expanded marketing efforts outside of the New
York region. Test results from hospital sites indicated that the Blood Volume
Analyzer was accurate and provided information that was important in a wide
variety of acute and chronic medical and surgical situations. The Company
manufactures its own injection kit components. The Company established a small
scale manufacturing facility in Oak Ridge, Tennessee for research and
development purposes. The Blood Volume Analyzer is also manufactured for Daxor
by an Original Equipment Manufacturer (OEM). This combination provides
flexibility to meet potential increased market demand. The injection kit filling
is performed by an FDA licensed radiopharmaceutical manufacturer. The Company
has received United States, European Common Market, and Japanese patents for its
Blood Volume Analyzer.

Blood volume measurement has been available for more than 60 years in formats
that required as much as four to eight hours of technician time with variable
degrees of accuracy. Due to the time required, certain technical shortcuts were
often used which reduced the accuracy of the measurement. An additional problem
was the difficulty of calculating an accurate expected normal blood volume for a
specific individual. Normal blood volume has been shown to vary in relation to
the degree of deviation from ideal weight. A leaner individual has a higher
blood volume percentage of body weight as compared to an obese individual. The
computations for an individual's normal expected blood volume were complex and
time consuming. The BVA-100(TM) Blood Volume Analyzer automated these
computations by calculating blood volume measurement to within accuracy of
approximately 98% while providing the precise measurement of the normal blood
volume for that specific individual based on the height, weight and sex of the
patient. In emergency situations, preliminary results can be available within 15
to 20 minutes, and final results within 45 to 50 minutes. The Company's patented
injection and collection kit, Volumex(TM), utilizes Albumin I-131 which is a
classic tracer used for blood volume measurement. The kit includes two matching
standards along with the pre-measured volumetric flow chamber. This kit has
resulted in the elimination of the previous time consuming steps whereby the
institution needed to create its own standards.

Measurement of blood volume is achieved by the use of an indicator or tracer
that is injected into a patient, and followed by the collection of timed blood
samples. The volume of blood in a patient is inversely proportional to the
dilution of the tracer. The measurement, while relatively simple in principle,
has been difficult to perform accurately and rapidly because of the high degree
of precision required in each step. The standard techniques require the hospital
or user to prepare an exact matching set of standards and with precise and
complete injection of the tracer. Due to the difficulty in achieving this type
of precision, blood volume measurements are currently performed in only a small
minority of hospitals in the United States. The standard tests, the hemoglobin
and the hematocrit, used to diagnose anemia, measure only the thickness
(percentage of red cells to plasma within the blood) and not the volume of an
individual's blood. These surrogate or proxy tests are well known to be
misleading in many situations where blood volume is abnormal. In acute
situations of blood loss, such as during surgery or after trauma, it may take as
long as 24 to 72 hours for the hematocrit to accurately or reasonably reflect
the degree of blood loss.

Patients may have delayed transfusions because the full degree of blood loss is
not reflected by these proxy tests. Delayed transfusions or fluid replacement
may result in


                                       2
<PAGE>

serious complications, including the death of the patient. The largest potential
use for the Blood Volume Analyzer is for evaluation and treatment of
outpatients' medical problems. Many disease conditions result in alterations of
blood volume which may have serious consequences for the patient.

Syncope, or sudden loss of consciousness, is a major cause for hospitalization
in the United States. As many as one million individuals per year experience an
episode of syncope. Patients who experience syncope may suffer severe injuries
when they collapse. Some patients may experience light-headedness without
complete loss of consciousness. Evaluation of such patients includes
neurological and cardiovascular testing, however, they do not usually include a
blood volume measurement. Low blood volume can be a predisposition to syncope.
Patients with this condition are frequently treated with different types of
drugs without precise knowledge of the underlying cause of the syncope.

The Cardiovascular Department of the Cleveland Clinic obtained a BVA-100(TM)
Blood Volume Analyzer in March 2000 for their Syncope Section. Results on over
one thousand patients in the Cleveland Clinic have demonstrated that a
significant percentage of such patients have moderate to severe hypovolemia (low
blood volume) which would not have been diagnosed without an actual blood volume
measurement. This scientific data has been submitted for publication in a
medical journal by Dr. Fetnat Fouad-Tarazi, Head of Hemodynamic and
Neuroregulation Lab, the Syncope Clinic, Department of Cardiology. The Cleveland
Clinic Cardiovascular Department is ranked number one in the United States
according to the annual US News & World Report survey of US Hospitals. The
hospital is ranked number 3 overall out of more than 6,200 hospitals in the
country. At the present time, most patients evaluated for syncope in hospitals
have tilt-table testing which identifies patients who may be at risk for
syncope. However, tilt-table testing does not differentiate patients who have
low blood volume from those who have neurological dysfunction of their blood
pressure. Only a blood volume measurement can provide this differential
diagnosis. The treatment for low blood volume involves medication to expand the
blood volume to normal. Neurological dysfunction involves different medical
treatment to control the low blood pressure. Blood volume measurement provides a
key test to facilitate correct treatment of patients.

According to the Journal of Clinical Geriatrics, one out of every three elderly
patients has a condition known as orthostatic hypotension. Orthostatic
hypotension is a condition when a person rises from a sitting or reclining
position, the blood pressure drops. This sudden drop in blood pressure may cause
dizziness or even loss of consciousness. One in eight elderly Americans
experience a hip fracture. It is unknown how many of these hip fractures are
caused by patients having a transient drop in blood pressure. A blood volume
measurement can help differentiate the cause of orthostatic hypotension. Some
patients with low blood volume caused by either low red cell volume or low
plasma volume can be treated with medications. Patients who have a normal blood
volume with orthostatic hypotension have a condition related to autonomic
dysfunction or ineffective control of the constriction of small blood vessels. A
medication is available for treating this condition.

A recent study by the Mayo Clinic estimated that there are 50 million Americans
who have hypertension (high blood pressure). It is reported that 70% of
hypertensive patients have their blood pressures inadequately controlled.
Hypertension is caused primarily by two variables. There is either a) excessive
blood (hypervolemia) or fluid retention within the circulation or b) excessive
tightening of the blood vessels (vasoconstriction). Diuretics are one major
category of drugs used to treat hypertension. Diuretics cause the kidney to
excrete salt and water thereby decreasing the blood volume and lowering the
blood pressure. A second major category of medications are vasodilators. These
drugs relax the blood vessels and lower the blood pressure. Within each of these
two major categories are drugs that work by different mechanisms, but they all
fall into one of these two main therapeutic categories, diuretics or
vasodilators. Treatment is often a trial and error approach because neither
vasoconstriction nor blood volume is actually measured in a patient (with rare
exception). One of the most serious complications of hypertension is loss of
kidney function (renal failure) which may require a patient to undergo permanent
renal dialysis.


                                       3
<PAGE>

Over the past year, the Company has received reports on patients treated for
hypertension with diuretics, who have a low blood volume. The physicians
treating these patients reduced or removed the diuretic therapy.
African-Americans have been reported to have significantly higher rates of
strokes and kidney failure as compared to Caucasians for comparable levels of
elevated blood pressure. Diuretic therapy is expected to benefit patients whose
elevated blood pressure is caused by an expanded blood volume. It may however be
harmful for patients whose high blood pressure is accompanied by low blood
volume. At the present time, there is inadequate data to determine whether
African- Americans, as a group, are more likely to be treated with diuretics.
The kidney is particularly vulnerable to low blood volume. It is well known that
certain medications, such as diuretics, can cause blood volume to decrease, and
increase the possibility of kidney failure. The measurement of blood volume in
the treatment of hypertension may help prevent these types of complications. By
measuring the blood volume within the patient, the physician can make a more
rational or scientific choice in regard to the medical therapy to be
administered.

The New England Journal of Medicine and the Journal of the American Medical
Association (JAMA) recently published 2 large-scale studies concerning the use
of diuretics vs. vasodilators. One of the studies that encompassed thousands of
patients found that diuretics were better. The other study which also
encompassed thousands of patients came to the opposite conclusion.
Unfortunately, in neither of these studies was blood volume measured. Physicians
have been puzzled by these conflicting results. The Mayo clinic, which purchased
the BVA-100(TM), previously reported that blood volume measurements can be
helpful in defining therapy. If every patient with hypertension had at least one
blood volume performed in their lifetime to help define optimum therapy, this
would be a very cost-effective test. This is because of the high degree of
complications such as kidney failure which hypertensive patient's experience.

Surgical patients who lose blood are particularly at risk for blood volume
derangements. Sometimes the first indication that a patient with a relatively
lower hematocrit has lost a large quantity of blood is the collapse of the
circulation. Sometimes physicians resort to the use of Pulmonary Artery
Catheterization (PAC). PAC involves the insertion of a catheter into a vein
through the right chamber of the heart and into the lung. This has frequently
been used as a surrogate technique to evaluate blood volume in critically ill
patients. However, PAC directly measures pressure, not volume. The Lutheran
Medical Center (New York) reported research on the first comparison of PAC with
direct blood volume measurements in patients. Their findings using the
BVA-100(TM) confirmed that PAC could be inaccurate and misleading in patients
who had significant blood volume deficits. Hypovolemia, or low blood volume, can
be particularly dangerous during surgery and may lead to sudden severe drops in
blood pressure. Such a drop in blood pressure, also known as shock, is
associated with strokes, heart attacks or even sudden death.

The Lutheran Medical Center has also published reports on the use of the Blood
Volume Analyzer in septic or toxic shock. Septic shock has death rates as high
as 40-70%. Using the BVA-100(TM), Lutheran Medical Center reported preliminary
results on 40 patients diagnosed with septic shock who were found to have
unanticipated low blood volume. The patients treated with fluids and blood to
restore their blood volume to normal levels had a markedly reduced death rate.
These findings, if verified on a larger scale, would be very important for
marketing the Blood Volume Analyzer. A primary goal of the Company is to have
the Blood Volume Analyzer become a standard of care within hospitals as part of
the decision-making process for administration of blood and intravenous therapy.
If these preliminary findings in the treatment of septic shock are verified, it
could be expected to have a significant impact on hospital demand for obtaining
a Blood Volume Analyzer.

Septic shock is a common daily occurrence in all hospitals. Major pharmaceutical
companies have attempted to find pharmaceutical agents that will reverse shock.
To date, these tests have been unsuccessful. A recent report on patients in
septic shock indicated a slight improvement in patients who were treated with a
new drug, Xigris. The cost of this drug is approximately $7000 per dose. Recent
reports from the V.A. Hospital in San Juan, Puerto Rico, which purchased a Blood
Volume Analyzer, are encouraging. Preliminary reports from the Intensive Care
Unit confirm that some patients treated for severe low blood volume were able to
recover without the use of Xigris. Other institutions are currently
investigating the use of blood volume measurement in Intensive Care Units.


                                       4
<PAGE>

If additional studies confirm that correction of blood volume should be the
primary focus on treating septic shock, then blood volume measurement would
become an integral part of the therapy for septic shock.

The cost of a diagnostic kit is approximately $299.00. The combined cost of
blood volume measurement and fluid and/or blood replacement would be
significantly lower than the anticipated cost of the septic shock drug which
only benefits a small percentage of patients.

Approximately 5 million individuals are treated annually for congestive heart
failure. The January 2000 issue of the American College of Cardiology reported
on a series of patients treated for congestive heart failure with low blood
volume and who were decompensated. Over-treatment of congestive heart failure is
very difficult to detect and symptoms of over-treatment can be confused with the
primary disease itself. It is estimated that $38 billion is spent annually on
treatment for congestive heart failure, of which $23 billion is spent annually
on hospital treatment of congestive heart failure patients. Congestive heart
failure is the number one reason for admission to hospitals in the US for
patients over 65 years of age. Three thousand patients annually receive heart
transplants. The overwhelming majority of patients treated for heart failure
must be treated with a combination of drugs. Two major heart studies from the
New York Presbyterian Medical Center and Hospital were recently published in the
leading cardiac journal Circulation. One study involved the treatment of anemia
in heart failure patients using the BVA-100(TM). The second study involved the
effects of Erythropoietin on exercise performance in anemic patients with
congestive heart failure. Senior authors were Ana-Silvia Androne, MD; Stuart D.
Katz, MD, et al; and Donna M. Mancini, MD; Stuart D. Katz, MD; et al.
respectively.

Dr. Stuart Katz, currently Associate Professor of Internal Medicine and
Cardiology at Yale University Medical Center at New Haven prepared additional
reports on blood volume measurement on heart failure patients utilizing the
BVA-100(TM). These papers have been accepted for publication in 2004 in the
Journal of the American College of Cardiology. An important finding in these
medical evaluations is that it is very difficult for physicians to accurately
evaluate congestive heart failure and blood volume status without actually
measuring the patient's blood volume. Nevertheless physicians are forced to make
major decisions to alter the patient's blood volume without the correct
knowledge of the patient's true blood volume status. Multiple case reports from
other cardiologists on the use of the Blood Volume Analyzer have confirmed that
congestive heart failure patients may have serious blood volume derangements
that cannot be correctly diagnosed without an actual blood volume measurement.

In 2003, the BVA-100(TM) was successfully installed in several top hospitals and
leading facilities around the nation. Among these was The Boeckman Burn Center
of the Children's Hospital Medical Center in Akron, Ohio. It is the first burn
unit in the United States to obtain a BVA-100(TM). Dr. Robert Klein, Director of
the Boeckman Burn Center stated that burn patients frequently have serious
complex abnormalities of blood volume which predisposes them to kidney failure.
Dr. Klein concluded that if the BVA-100(TM) proves to be effective in measuring
blood volume in these complex cases and avoiding some of these dreaded
complications, it will be an important advance in the treatment of burn
patients.

In May 2003, Grammercy Diagnostic Services obtained a BVA-100(TM). Dr. Peter
Rentrop, President and Medical Director, stated that blood volume measurement
was beneficial particularly in the treatment of congestive heart failure,
hypertension and syncope. Dr. Rentrop is an internationally recognized
interventional cardiologist with a long-standing special interest in nuclear
medicine and is a founding member of the American Society of Nuclear Cardiology.
Dr. Rentrop and his group were among the first to use streptokinase therapy to
halt a heart attack's progress. He concluded that streptokinase therapy may
preserve the heart's primary function of pumping blood.

Grammercy Diagnostics is a model of a free standing facility for non-hospitals.
Grammercy performs over four thousand nuclear medical diagnostic procedures
annually. In addition to Dr. Rentrop, there are thirteen additional
cardiologists who are affiliated with the group.


                                       5
<PAGE>

Researchers at Columbia Presbyterian are in the midst of a study involving
patients with so-called diastolic heart failure utilizing the BVA-100(TM).
Diastolic heart failure is a major category of difficult to treat heart failure
patients where a blood volume measurement may provide essential information for
optimum treatment. Results are expected to be available later this year.

Low red cell volume, or Anemia, is a common occurrence in patient's undergoing
chemotherapy for AIDS or cancer. Epogen and Procrit, which are manufactured by
the Amgen Corporation, can provide therapy for such conditions. Procrit is
distributed by the Ortho Division of Johnson & Johnson. The standard surrogate
tests, hematocrit and hemoglobin, may not reflect the full degree of decreased
red blood cell volume in such patients. A blood volume measurement can detect
unrecognized low blood volume or "hidden anemia" in such patients that may be
contributing to a profound feeling of weakness common in such conditions. A
patient who has a low blood volume that is undetected may have an artificially
elevated hematocrit. Such a patient may experience severe fatigue and other
symptoms that could be improved by appropriate treatment. These patients have a
form of "hidden anemia" and are not optimally treated. It is only with the use
of a blood volume measurement that the lower red cell volume could be detected
and treated. Blood volume measurement that could detect low blood volume in
patients with cancer, kidney disease, or heart failure could significantly
increase the justification and use of these blood stimulants.

Chronic fatigue syndrome is a condition said to affect approximately one million
Americans, particularly patients with low blood pressure. Low blood volume has
been reported to be a factor in such conditions. The ability to measure blood
volume with a high degree of precision and accuracy may identify patients with
low blood volume who are not optimally treated at the present time.

There are over 4 million patients who receive blood transfusions every year. The
Company believes that if the BVA-100(TM) were available in every hospital, it
would be feasible for the hospital to routinely perform a blood volume test on
every patient for whom a blood transfusion appeared to be indicated. Several
manufacturers including Northfield Laboratories, Biopure, and Hemosol
Corporation are testing blood substitutes. To date, despite many attempts by
these companies, none of them have received FDA approval for these procedures.
These substitutes can be used for surgical procedures instead of donor
transfusions. These artificial blood substitutes have the advantage of a long
shelf life and the ability to be sterilized. They have the disadvantage of a
shortened half-life in the body after transfusion. None of the companies elected
to use a BVA-100(TM) in their studies. In these studies, patients were being
treated with a blood substitute without knowing what the patient's blood volume
was at the beginning of the transfusion and the patients' blood volume at the
end of the transfusion. This type of information can be readily available if the
BVA-100(TM) was used in studies involving blood substitutes. Lack of this type
of basic information may be one of the factors behind the FDA's unwillingness
over the past 10 years to license any of these types of hemoglobin substitutes.

There have been recent reports in the New England Journal of Medicine that as
many as 60% of patients undergoing Cardiac Bypass Surgery (CABG) experience some
degree of measurable permanent brain damage such as memory loss. Under current
transfusion practices, patients may undergo major surgery with half the
concentration of normal red cells. The practice of undertransfusion is
widespread. In the Journal Transfusion, Dr. Robert Valeri, a senior researcher
at the Boston Naval Hospital estimated that there may be as many as 40,000 heart
attacks per one million operations due to undertransfusions. The Company is
attempting to initiate a cooperative program which will involve the use of blood
volume measurement combined with the use of blood substitutes during surgery.
The Company believes that it can provide a significant advantage to companies
currently testing blood substitutes on patients without a precise knowledge of
the patient's actual blood volume. Patients who have low blood volume at the
start of surgery may respond very differently than a patient with a normal blood
volume who is treated with a blood substitute. The current guidelines for the
use of these products are based on hemoglobin and hematocrit measurements. These
tests, however, may be very misleading in regard to the total amount of red
cells a patient has in his/her body.


                                       6
<PAGE>

The Company is currently exploring the development of low blood volume detection
and treatment programs in conjunction with several hospitals. Many patients
undergoing elective surgery donate blood to themselves prior to that surgery.
Some patients have undetected low blood volume and should not be donating blood.
Undetected "hidden anemia" can be corrected if diagnosed prior to surgery by the
use of medications such as Epogen or Procrit. A woman has 16-18% less red cell
volume than a man of equal height and weight. Women suffer from a higher rate of
complications and require more transfusion during Cardiac Bypass Surgery (CABG).
The use of low blood volume detection and treatment programs can result in a
significant improvement in patients at the time they are undergoing surgery.
Common complications from acute low blood volume are strokes, heart attacks, and
kidney failure.

Surgical patients who experience these complications require extended hospital
stays for which the hospitals are often not reimbursed. Hospitals operate under
a Diagnostic Regulatory Guideline (DRG) system for reimbursement. The DRG system
means that a hospital will be reimbursed according to a diagnosis, not according
to the number of days that a patient spends in the hospital.

Hospitals, however, have a significant monetary incentive aside from the desire
to provide better patient care, to avoid having patients undergo surgery in a
blood depleted state. A low blood volume detection and treatment program can
significantly improve the opportunity for patients to avoid complications from
hypovolemia as well as transfusions with donor blood. The Company believes that
the most significant market for its blood volume measurement equipment consists
of approximately 8,500 hospitals and Radiology Imaging Centers in the United
States.

The Company believes that there is an additional international market of 10,000
to 14,000 potential users of its BVA-100(TM). Blood volume measurement is an
approved test with six separate CPT codes. Reimbursement has been received from
a number of insurance companies, including Medicare for measurement of blood
volume using the BVA-100(TM). Reimbursement is particularly important for
hospitals because they may receive additional reimbursement and income from
non-hospitalized patients who undergo blood volume measurement.

SCIENTIFIC MEDICAL SYSTEMS SUBSIDIARY (wholly owned by Daxor)

BLOOD BANKING

The Company's blood bank is the only one in New York that allows people to store
their own red blood cells (RBC) for up to ten years. In 1985, the Company
established the first facility in the United States for long-term autologous
(self-storage) blood banking. The blood banking industry is a group of
for-profit and not-for-profit corporations whose total revenue is estimated to
exceed six billion dollars.

Utilizing cryobiology technology, frozen blood is capable of being stored for up
to 20 years, however, the current legal limit is 10 years for RBC. The present
donor system of blood transfusions presents risks to those individuals receiving
blood. This is a risk that can be avoided by utilizing one's previously stored
blood. There are approximately 15-18 million blood transfusions administered
annually to 4 million patients. Despite improved testing, significant risks
still remain from diseases such as West Nile Virus, which can be transmitted by
transfusion. Diseases such as Hepatitis and HIV can also be transmitted by
infected donors who may test negative for up to 6 months after the initial
infection. The FDA is particularly cautious and will not permit an individual
who received a transfusion to donate blood to another person for a period up to
1 year after receiving the transfusion. This regulation is designed to exclude
donors who may be infected but undetectable by the standard tests used for
screening donors.

The risks of infection and other complications are compounded by the frequent
withholding of blood from severely anemic patients by their physicians because
of the known risks of transfusion. It is a common medical practice to replace
the first three pints of lost blood with three pints of sterile water or their
equivalent. This problem has not been brought to the public's attention, but it
is widely known among physicians who have treated patients who have lost blood.
The number of patient's who suffer major complications, including sudden death
from under-transfusion, is unknown but significant.


                                       7
<PAGE>

The Blood Volume Analyzer has the potential to detect under-transfusion in such
individuals before complications occur. Physicians who fear the complications of
transfusion with potentially contaminated blood do not have these concerns when
patients use autologous blood (self-storage).

The Company believes that an educational process can establish the advantages of
autologous blood storage. Education can also overcome opposition to any change
in the current blood banking system from established tax-exempt (non-profit) and
profit-making entities. The Company believes that it can work with some
voluntary blood banks and hospitals to establish joint marketing of long term
frozen personal blood storage programs.

Blood Banking services are provided by a broad spectrum of organizations.
Approximately one-half of the blood supply used for transfusions, are supplied
by the American Red Cross and its affiliates. The other portion is supplied by
various other tax-exempt and for-profit organizations. Some hospitals operate
their own donor services, but require the services of outside vendors such as
the Red Cross for adequate supplies of blood products. At the present time there
are no other organizations providing long-term personal frozen blood storage in
the Northeastern United States. It is the Company's intentions to form alliances
with other short-term donor blood banks to expand frozen personal blood storage
services.

The Company views personal blood storage as a supplement to and not as
competition to other existing blood donor services.

Idant (Division of Scientific Medical Systems, a wholly owned subsidiary of
Daxor Corporation) Semen (Sperm) Banking

In 1985, Idant was the first semen bank to institute an AIDS quarantine period
for frozen semen. Viruses such as HIV and Hepatitis B or C may be undetectable
for up to six months in infected individuals. By freezing the semen of donors
and re-testing the donor six months later, the risk of Hepatitis or AIDS can be
virtually eliminated. In 1989, New York State and a number of other states
enacted laws requiring sperm banks to freeze and quarantine sperm for a minimum
of six months. The donors are tested at the beginning and at the end of the
six-month period. By storing semen from a large cross-section of donors, Idant
is able to offer anonymous donor semen with varying physical characteristics
that meet our client's needs. The Company maintains a complete physical
description of each donor on file and matches multiple physical characteristics
and additional special characteristics sought by the family to those of the
sterile father. The Company also provides, on request, special screening for
rare hereditary recessive genetic traits. The increased likelihood of a child
who resembles his recipient father can make the child, who is conceived via
artificial insemination, much more psychologically acceptable to the father.

Storage of Sperm for Personal Use

Idant pioneered both the technology and the commercial application of long-term
preservation of human sperm for use in artificial insemination. The division has
provided frozen semen services to physicians worldwide. Idant holds
approximately 50,000 human semen units in long-term storage at its central New
York City facility. The Company was the first semen bank in the state of New
York, out of more than 50 licensed banks, to be accredited by the American
Association of Tissue Banks. Idant provides semen storage services for clients
which remain viable for many years. Idant has received confirmation of normal
births from semen stored as long as 16 years. The Company's facility is used by
men who, for a variety of reasons, anticipate impairment of their ability to
father children and by men who have been found to be marginally fertile. These
men may now be able to have children by use of assisted reproductive techniques
that increase their probability of fertility. The facility is also used by men
who plan to undergo sterilization by vasectomy, but who believe that they might
desire children in the future. Artificial insemination using stored sperm is
much more effective and less expensive than present techniques of vasectomy
reversal.


                                       8
<PAGE>

In addition, patients with a variety of diseases, including many types of
cancer, store semen prior to undergoing treatment by chemotherapy or radiation.
By utilizing cryogenic preservation facilities, these patients, who are
frequently in their teens or twenties, will be able to father their own children
after cancer treatment, despite the high risk of sterility and birth defects
associated with treatments. The Company receives referrals for these services
from multiple sources, primarily physicians.

The Company uses a customized carousel canister system in its sperm bank storage
system. This permits retrieval of specimens from lower levels without removal of
upper specimens.

Most other banks use a "rack and cane" pull-up system, which requires removal of
upper specimens from the tank to retrieve specimens at lower levels. In such a
bank, a specimen may be exposed to a temperature change of -321oF (the
temperature of the liquid nitrogen) to room temperature of 72oF more than 100
times during its storage lifetime. This will result in a gradual degradation of
the specimen. In the Idant system the specimen remains under liquid nitrogen
almost continuously while in storage.

The Company is aware of only one other semen bank, which uses the carousel
system for long-term storage of semen. Idant periodically spot-checks its bank
storage to test viability of selected specimens of stored semen. The results of
these spot-checks have shown sperm samples held in excess of 23 years, at minus
321 degrees, to have almost no loss in viability or change in condition.

Patent and Copyright Protection

The Company has received separate United States patents on its Blood Volume
Analyzer BVA-100(TM) and for its Volumex(TM) injection kit. These are the only
US patents ever issued for an instrument dedicated to the measurement of total
human blood volume for a specific individual. The Company received a European
patent covering 12 countries. The Company received the first patent ever issued
for an instrument in Japan to measure human blood volume. The instrument is
designed to work with an injection kit manufactured by the Company. It is
theoretically possible to use the Blood Volume Analyzer without the kit by
preparing the reagents used for the test. However, the cost and time for such
preparations would be uneconomical and it is unlikely that a purchaser of the
instrument would use it without purchasing the reagent kit. This is the first
U.S. patent ever issued for a system, which permits a fixed quantitative amount
of isotope to be injected for diagnostic purposes. The injection system was
specifically designed for use with the BVA-100(TM). However, it can be used for
other diagnostic test purposes where a precise complete quantitative injection
of a diagnostic reagent is required.

The Company expects to file additional patents for tests associated with the
BVA-100(TM). These include filing a patent for equipment which will automate the
measurement of glomerular filtration rate of the kidney. This is a very
important and sensitive test of kidney function. At the present time this test
is infrequently performed because of the difficulty in the current methodology.
The Company believes that it can automate this process which will make it more
feasible for regular medical use.

A patent will be filed for the measurement of total albumin. Albumin is a major
carrier of human protein in the body. Albumin derangement is common in many
disease states. Burn patients in particular have serious loss of albumin, and
replacement quantities may be difficult to calculate. Patients in congestive
heart failure also frequently have albumin derangements. The ability to measure
total body albumin accurately would be expected to facilitate more precise
therapy.

The Company is also exploring the submission of a patent for methodology of
improving client identification in its semen bank. It is introducing additional
patient protection for stored donor semen which may be eligible for patent
protection. In the 33 years of the Bank's operations, it has never had a mix-up
in any stored specimen.

Marketing

The Company is marketing its Blood Volume Analyzer either on a direct sale,
lease, or an instrument loaner basis to potential users. Primarily, users are
expected to be hospitals, surgi-centers, and imaging centers (radiology). The
Company also has been


                                       9
<PAGE>

demonstrating its equipment at major trade shows that relate to the following
departments within hospitals such as Nuclear Medicine, Nuclear Cardiology,
Cardiology, Intensive Care, Trauma, and the ER. The Company recognized after the
initial beta testing that it was important to have the Blood Volume Analyzer at
leading medical institutions. Publications and reports from such institutions
are particularly important for acceptance by the general medical community.
During the past 2 years, a number of leading facilities acquired a Blood Volume
Analyzer. The US News and World Report provides an annual ranking of 6200
Hospitals in the United States. The Mayo Clinic, and The Cleveland Clinic,
ranked respectively 2 and 3 in the annual ranking of hospitals have a
BVA-100(TM). The Cleveland Clinic Cardiovascular Department ranked number 1 in
the US will soon be reporting on over 1000 patients on who blood volume testing
was performed. In addition to these facilities, Vanderbilt Medical Center, and
the New York Hospital Presbyterian Medical Center ranked in the top 20 in the
Annual Survey of Hospitals also have a Blood Volume analyzer. The National
Institutes of Health, the leading US government research agency, has acquired a
Blood Volume Analyzer.

The Company's marketing efforts are focused on documenting the beneficial
effects of blood volume measurement as well as developing cost benefit analysis
studies. Hospitals and health facilities are exceedingly cost conscientious in
regard to acquiring additional medical technology. Blood volume measurement is
an approved and reimbursable Medicare test. Such studies are particularly
important to HMO's which focus on avoiding hospitalization when possible. As
these studies become available, they will be incorporated into the marketing
program of the Company.

In September 2002, the Company hired a National Sales Manager and 3 other
Regional Sales Managers with extensive experience in the medical device and
nuclear medicine field. In the past 9 months, several different sales models
were tested. It was determined that the best model was a National Sales Manager
with regional sales representatives. John Reyes Guerra, one of the original
regional vice presidents was made National Sales Manager. The sales staff was
expanded to 10 sales personnel plus 4 support personnel. As part of the support
system, one sales representative was hired to contact all physicians in the
regions and to assist in marketing efforts. If this concept is successful, the
Company will institute a similar structure in other regions. Working in
conjunction with the existing staff, they have begun to develop the foundations
for an in depth marketing program utilizing the results from major teaching
hospitals. The Company believes that this is the appropriate time to continue
expanding marketing and sales efforts. The Company is also exploring the hiring
of a separate staff to market blood banking services.

The Company's website (http:// www.daxor.com) contains extensive detail about
the BVA-100(TM) Blood Volume Analyzer as well as examples of actual cases (with
patient identities removed). The website permits rapid communication between
marketing personnel and potential users prior to an onsite visit.

Competition

Blood Volume Analyzer

The medical technology market is intensely competitive. However, there are no
direct competing instruments manufactured or marketed that perform rapid
semi-automated blood volume analysis, such as the BVA-100(TM). The Company
believes that its receipt of a United States, European and Japanese patent for
its Blood Volume Analyzer provides significant protection against any future
potential competition in the blood volume analysis field.

The receipt of the U.S. patent for the injection kit system provides significant
additional protection as the Company believes that the kits will be a major
source of revenue. The Company believes that its main hindrance to market
acceptability will be the need to demonstrate that its blood volume measurement
equipment is capable of producing accurate data on a cost effective basis. Test
kit costs will be modest relative to the cost of the critical information
derived from the test. The Company is evaluating the filing of additional
patents in regards to its injection collection kit system for blood volume
analysis.


                                       10
<PAGE>

Blood Banking

The Idant frozen blood bank is the only facility that provides long-term
personal frozen blood storage in the Northeastern United States. Multiple
companies which previously attempted to provide long-term personal blood storage
to members of the public were unsuccessful. To date, the Company has not made a
profit from its blood banking services. The Company believes however that
additional technology which enables longer use of frozen blood after it is
stored may enable such services to eventually become sustainable financially and
profitable.

Semen Banking

There are at least 300 sperm banks in the United States operated by either
commercial entities or by academic institutions. The Idant semen bank was the
first semen bank in the State of New York that was accredited by the American
Association of Tissue Banks. There are 10 semen banking organizations in the
United States that have achieved this accreditation. The Company has developed a
web site www.Idant.com, which will be helpful for marketing purposes.

Regulation

The development, testing, production and marketing of medical devices is subject
to regulation by the FDA under the Federal Food, Drug and Cosmetic Act, and may
be subject to regulation by similar agencies in various states and foreign
countries.

The governing statutes and regulations generally require manufacturers to comply
with regulatory requirements designed to assure the safety and effectiveness of
medical devices. The FDA clearance for marketing of the Blood Volume Analyzer,
BVA-100(TM), and the associated quantitative injection kit marks one of the most
important milestones in the history of Daxor. The products manufactured by and
for the Company in regard to the BVA-100(TM) are subject to continuing FDA
regulations and inspections.

The New York State Department of Health regulates the Company's Idant semen and
blood bank within New York State. The Idant Semen Bank and Blood Bank are
divisions of Scientific Medical Systems, which is a subsidiary wholly owned by
the Daxor Corporation. Scientific Medical Systems has its own separate
directors. These facilities are licensed and annually inspected by the New York
State Department of Health.

Labor Force

On March 24, 2004, the Company had a labor force of 35, which was leased through
ADP TotalSource. The Company believes that its labor force relations are good.

Item 2. Properties

In December 2002, the Company signed a new thirteen-year lease for its existing
facility at the Empire State Building. The Company has occupied this space since
January 1992. The company currently occupies approximately 7,500 square feet.
The lease has a two year option for renewal after thirteen years. There are
options for an additional 18,000 square feet of space. The Company has a
manufacturing facility in Oak Ridge, Tennessee which is currently manufacturing
the BVA-100(TM) Blood Volume Analyzers.

Item 3. Legal Proceedings

The Company has pending several claims incurred in the normal course of
business, which, in the opinion of management, as well as the advice of outside
legal counsel, there is no merit to these claims nor will they have a material
effect on the financial statements.


                                       11
<PAGE>

Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of the Company's shareholders during the
fourth quarter of 2003.

Part II.

Item 5. Market for Registrant's Common Equity and Related Stockholder Matters

The common stock is traded on the American Stock Exchange under the symbol DXR.

2003

                                                       High           Low
                                                       ----           ---
      First Quarter                                    16.15         13.86
--------------------------------------------------------------------------------
      Second Quarter                                   16.25         11.60
--------------------------------------------------------------------------------
      Third Quarter                                    17.65         14.50
--------------------------------------------------------------------------------
      Fourth Quarter                                   15.40         13.50
--------------------------------------------------------------------------------

2002

                                                       High           Low
                                                       ----           ---
      First Quarter                                    19.65         17.35
--------------------------------------------------------------------------------
      Second Quarter                                   19.09         16.50
--------------------------------------------------------------------------------
      Third Quarter                                    17.50         15.00
--------------------------------------------------------------------------------
      Fourth Quarter                                   16.10         14.00
--------------------------------------------------------------------------------

On February 27 2004, the Company had approximately 201 holders of record of the
Common Stock. The Company believes there are approximately 1600 beneficial
holders.

The Company paid a single cash dividend, $.50, on the Common Stock in 1997. Any
future dividends will be dependent upon the Company's earnings, financial
condition and other relevant factors.


                                       12
<PAGE>

ITEM 6. SELECTED FINANCIAL DATA

      The following table sets forth certain selected financial data with
respect to the Company and is qualified in its entirety by reference to the
financial statements and notes thereto, from which these data were derived,
included elsewhere in the report.

Selected Operations Statement Data:

<TABLE>
<CAPTION>
                                                             Year Ended December 31,
                                       2003            2002            2001           2000            1999
                                   -----------     -----------     -----------    -----------     -----------
<S>                                <C>             <C>             <C>            <C>             <C>
Revenues and other income:
Operating revenues                 $ 1,013,647     $   767,608     $   591,692    $   635,868     $   500,969
Dividend income                      1,897,669       1,858,025       1,860,289      1,842,583       1,856,119
Gains on sale of investments           238,550          40,610          97,719         57,399         469,595
Other revenues                          15,571          35,694         166,676        109,920          74,407
                                   -----------     -----------     -----------    -----------     -----------
Total revenues and other income      3,165,437       2,701,937       2,716,376      2,645,770       2,901,090
                                   -----------     -----------     -----------    -----------     -----------

Costs and other expenses:
Operations of laboratories
  & costs of production              1,489,264         805,985         814,657      1,052,000         833,751
Selling, general and
  administrative                     2,669,229       2,050,546       1,482,438      1,450,623       2,017,364
Interest expense, net                   83,133          39,257         119,926        198,341         147,105
                                   -----------     -----------     -----------    -----------     -----------
Total costs and other expenses       4,241,626       2,895,788       2,417,021      2,700,964       2,998,220
                                   -----------     -----------     -----------    -----------     -----------

Net income (loss) before
  income taxes                      (1,076,189)       (193,851)        299,355        (55,194)        (97,130)
Provision for income taxes                   0               0               0              0               0
                                   -----------     -----------     -----------    -----------     -----------

Net income/(loss)                  $(1,076,189)    $  (193,851)    $   299,355    $   (55,194)    $   (97,130)
                                   ===========     ===========     ===========    ===========     ===========

Weighted average number of
  shares outstanding                 4,647,350       4,662,947       4,664,909      4,675,826       4,721,492
                                   -----------     -----------     -----------    -----------     -----------

Net income (loss) per common
  equivalent share                 $     (0.23)    $     (0.04)    $      0.06    $     (0.01)    $     (0.02)
                                   ===========     ===========     ===========    ===========     ===========
</TABLE>

Selected Balance Sheet Data:

<TABLE>
<CAPTION>
                                               Year Ended December 31,
                           2003           2002           2001           2000           1999
                        ----------     ----------     ----------     ----------     ----------
<S>                     <C>            <C>            <C>            <C>            <C>
Working capital         36,044,529     33,136,421     34,979,217     38,309,247     28,869,309

Total assets            48,300,532     41,573,565     43,540,153     49,575,118     35,846,065

Total liabilities       11,883,362*     8,026,668      8,211,186     10,903,280      6,566,496

Shareholders' equity    36,417,170     33,546,897     35,328,967     38,671,838     29,279,569

Return on equity*             0.00%          0.00%          0.77%          0.00%          0.00%
</TABLE>

*     Return on equity is calculated by dividing the Company's net income for
      the period by the shareholders' equity at the beginning of the period.

*     Total liabilities include deferred taxes of $8,531,081 for unrealized
      Gains in 2003.


                                       13
<PAGE>

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

GENERAL

Year end 2003 was the first time that revenues from Daxor's BVA division
exceeded Idant's revenues. Idant Laboratories subsidiary contributed 45%,58% and
54% of operating revenues in 2003, 2002 and 2001 respectively. The Company's
operations in semen banking and blood banking (laboratories) have received
limited promotion however, the Company has taken steps to increase awareness of
these services. The potential market for the Blood Volume Analyzer is
significantly larger than the Company's current operations. The Company
anticipates that proceeds from Daxor's Blood Volume Analyzer will be the primary
source of revenue in the immediate future. The Company believes that the
potential market for blood volume measurement and analysis is between 15-20
million tests per year. Successful penetration of even a small fraction of the
market would significantly change the Company's structure. The Company intends
to focus its major marketing efforts on the Blood Volume Analyzer.

During fiscal year 2003 and early 2004, Daxor expanded its sales and marketing
staff. The Company intends to increase its marketing efforts to add to its
operational income. Some of the steps the Company had undertaken, such as
consolidating certain manufacturing facilities at Oak Ridge, Tennessee and
simultaneously contracting with an Original Equipment Manufacturer (OEM) will
permit greater economies of scale. The Company's primary focus will be to
increase operating revenues even if this initially results in lower profits or
even a loss.

YEAR ENDED DECEMBER 31, 2003 AS COMPARED TO DECEMBER 31, 2002

Total operating revenues increased by 32% to $1,013,647 in 2003, up from
$767,608 reported in 2002. Dividend income earned on the Company's securities
portfolio was $1,897,669 an increase from the $1,858,025 reported in 2002. Gains
on the sale of investments were $238,550 in 2003 as compared to $40,610 in 2002.
Operating revenues increased to $1,013,647 in 2003, an increase of 32% from
$767,608 in 2002. Total costs and expenses increased by 47% to $4,217,364 in
2003 from $2,873,442 in 2002. Total income increased by 17% to $3,165,437 in
2003, up from $2,701,937 reported in 2002. Total income includes dividend
income, gains on sale of investments, and other miscellaneous income. The
increase in operating expenses was primarily due to increased hiring of
personnel and additional marketing and selling expenses related to the Blood
Volume Analyzer. The Company anticipated these increased operating expenses and
intends to continue expanding its marketing and sales staff. There was a net
loss before income taxes of $(1,076,189) in 2003 vs. a loss of ($193,851) in
2002. In 2003, the Company's total assets were $48,300,532 with loans
(short-term) totaling $2,502,106. The Company's asset to debt ratio in 2003 was
19.3:1. In 2002, the Company's total assets were $41,573,565 with loans
(short-term) totaling $1,434,046. The Company's asset to debt ratio in 2002 was
29:1.

YEAR ENDED DECEMBER 31, 2002 AS COMPARED TO DECEMBER 31, 2001

Total operating revenues increased by 30% to $767,608 in 2002, up from $591,692
reported in 2001. Dividend income earned on the Company's securities portfolio
was $ 1,858,025 a decrease from the $1,860,289 reported in 2001. Gains on the
sale of investments were $40,610 in 2002 as compared to $97,719 in 2001.
Operating revenues increased to $767,608 in 2002 from $591,692 in 2001. Total
cost and expenses increased to $2,873,442 from $2,347,270 in 2001. This increase
was partially caused by increased hiring of personnel and additional marketing
and selling expenses. Total income was $2,701,937 in 2002, down from $2,716,376
reported in 2001. Total income includes dividend income and gains on sale of
investments. There was a net loss before income taxes of ($193,851)in 2002 vs.a
net income before income taxes of $299,355 in 2001.

LIQUIDITY AND CAPITAL RESOURCES

The Company's management has pursued a policy of maintaining sufficient
liquidity and capital resources in order to assure continued availability of
necessary funds for the viability and projected growth of all ongoing projects.

The Company maintains its diversified securities portfolio comprised primarily
of electric utilities preferred and common stocks. The income derived from these
investments has helped to offset the operating and marketing expenses of
developing


                                       14
<PAGE>

the Blood Volume Analyzer. The Company has followed a conservative policy of
assuring adequate liquidity so that it can expand its marketing, and research &
development without the necessity of raising additional capital. The securities
in the Company's portfolio were selected to provide stability of both income and
capital.

At December 31, 2003, the Company had $2,502,106 in short-term debt vs.
$1,434,046 in 2002. At year-end 2003, shareholders' equity was $36,417,170. At
year-end 2002, the Company had shareholders' equity of $33,546,897. At December
31, 2003 the Company's security portfolio had a market value of $47,399,159 vs.
$40,573,162 in 2002. In 2002, the Company's sales staff was comprised of 4
salesmen plus 3 support personnel. The Company has recently expanded to 11 sales
staff and 4 support personnel.

In 1998, the Company purchased the assets of Wellport Manufacturing Company in
Rochester, New York. They had previously manufactured the MAX-100(TM) portion of
the injection and collection kit. The Company now manufactures its own
collection kit. The final filling and shipping of the kit is performed by an FDA
licensed radiopharmaceutical manufacturer. In 2000, the Company leased space in
Oak Ridge, Tennessee to manufacture its own BVA-100(TM) Blood Volume Analyzers.
In 2003, the Company anticipated to sell more BVA-100(TM)'s, and therefore
contracted for additional space in Oak Ridge to manufacture the collection kits,
as well as have capacity for final assembly and shipping of the BVA-100(TM)
system. The Company has a separate contract with an Original Equipment
Manufacturer to manufacture additional Blood Volume Analyzers. The Company is
reviewing options to purchase some of the original equipment manufacturers who
provide various parts of the BVA-100(TM) Blood Volume Analyzer system. The
Company experimented on a limited basis with independent medical distributors in
2001- 2003. These marketing attempts did not produce successful results and it
motivated the Company to employ its own dedicated staff for marketing and sales.
The Company believes that as wider acceptance is achieved and blood volume
measurement becomes a standard of care for various surgical and medical
conditions, independent medical distributors may be effective. This will
initially increase expenses faster than revenues, but it is expected to
ultimately result in a more rapid acceptance of the BVA-100(TM) technology.

The Company sells, as well as offers to lease, or rent its Blood Volume Analyzer
BVA-100(TM) as part of an overall marketing plan. The Company, also as part of
its marketing program, will loan an instrument for a limited time period,
however, facilities evaluating the instrument must pay for the kits. The Company
established Daxor Capital with a relationship through De Lage Landen ("DLL").
Based in the Netherlands, it is one of the largest private banks in the world.
De Lage Landen has extensive experience in capital equipment leasing through its
existing relationships with premier corporations such as Toshiba and Abbott. The
significance of this relationship is as sales through leases increases, Daxor
will not have to diminish its capital outlay for equipment as DLL will fund the
net present value of the lease upon installation of the equipment. In an effort
to obtain the best rates for our clients, the Company will also work with other
independent leasing firms.

The Company is also developing a blood volume laboratory staffing program with
one of its clients. Under such program, the Company may provide management
services as well as equipment services. With respect to blood banking, recent
technological advances have significant potential in proving the safety of blood
banking. A major handicap for the use of frozen blood was the fact that after it
was thawed, the blood had to be used within 24 hours. New technology approved by
the FDA and utilized by the U.S. military, enables blood to be used for up to 2
weeks after it has been thawed. The Company, in addition to its regular frozen
blood banking services, intends to implement this type of program. This type of
program will initially produce a net loss, but the Company believes that there
is sufficient potential demand that such a program will be self sustaining.

Year-end 2003 finds the Company in a satisfactory financial position with
adequate funds available for its immediate and anticipated needs. The Company
plans its budgetary outlays on the assumption that the raising of additional
financial capital may be difficult in the next 2 to 4 years. The Company
believes that its present liquidity and assets are more than adequate to sustain
the additional expenses associated with an expanding sales and marketing
program.


                                       15
<PAGE>

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

The Company is currently not exposed to any risk from currency fluctuations. The
Company's investment portfolio is a major source of revenue. A summary of the
status of this portfolio as of December 31, 2003 and 2002 is reported in
Footnote #2 of the Consolidated Financial Statements. The market value of this
portfolio is related to fluctuations with the electric utility industry. Between
5% and 10% of the Company's portfolio are non-utilities. The Company will sell
puts on stocks that it is willing to own. The Company neither sells naked calls
nor engages in derivative transactions. Fluctuations in the value of these
holdings for the past 5 years are reflected and closely correlated with changes
in the total assets of the Company (see item 6: selected financial data).

Item 8. Consolidated Financial Statements

Index to Consolidated Financial Statements

Report of Independent Registered Public Accounting Firm
Report of Independent Auditors
Consolidated Balance Sheets - December 31, 2003 and 2002
Consolidated Statements of Operations for the years ended December 31, 2003,
  2002 and 2001
Consolidated Statements of Stockholders' Equity and Comprehensive Income for
  the years ended December 31, 2003, 2002 and 2001
Consolidated Statements of Cash Flows for the years ended December 31, 2003,
  2002 and 2001.
Notes to Consolidated Financial Statements

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders of
Daxor Corporation:

We have audited the accompanying consolidated balance sheet of Daxor Corporation
and Subsidiary (the "Company") as of December 31, 2003, and the related
consolidated statements of operations, stockholders' equity and comprehensive
income, and cash flows for the year then ended. These consolidated financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audit. The financial statements of the Company as of
December 2002 and 2001, and for the years then ended, were audited by other
auditors whose report dated March 17, 2004 expressed an unqualified opinion on
those statements.

We conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States of America). Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of the Company as of
December 31, 2003, and the results of its operations and cash flows for the year
then ended, in conformity with accounting principles generally accepted in the
United States of America.


Rotenberg Meril Solomon Bertiger & Guttilla, P.C.
Saddle Brook, New Jersey
April 6, 2005

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors and Shareholders of Daxor Corporation:

We have audited the accompanying consolidated balance sheets of Daxor
Corporation as at December 31, 2002 and 2001, the related consolidated
statements of income, shareholders' equity and comprehensive income, and cash
flows for each of the two years in the period ended December 31, 2002.

These financial statements are the responsibility of the Corporation's
management. Our responsibility is to express an opinion on these financial
statements and based on our audits.

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such financial statements present fairly, in all material
respects, the financial position of Daxor Corporation as at December 31, 2002
and 2001, and the results of their operations and its cash flows for each of the
two years in the period ended December 31, 2002 in conformity with generally
accepted accounting principles.


Frederick A. Kaden & Co.

Brentwood, New York
March 24, 2003


                                       16
<PAGE>

                                DAXOR CORPORATION
                        CONSOLIDATED FINANCIAL STATEMENTS
================================================================================
DAXOR CORPORATION
CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                 December 31,      December 31,
                                                     2003              2002
                                                 ------------      ------------
<S>                                              <C>               <C>
-------------------------------------------------------------------------------
ASSETS
-------------------------------------------------------------------------------

CURRENT ASSETS
Cash and cash equivalents                        $      3,324      $     13,035
Available-for-sale securities                      47,399,159        40,573,162
Accounts receivable                                   137,008           211,979
Inventory                                             146,185           149,225
Prepaid expenses and other current assets             242,215           215,688
                                                 ------------      ------------

Total Current Assets                               47,927,891        41,163,089

Property and equipment, net                           303,373           338,875
Other Assets                                           69,268            71,601
                                                 ------------      ------------

Total Assets                                     $ 48,300,532      $ 41,573,565
                                                 ============      ============

-------------------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
-------------------------------------------------------------------------------

CURRENT LIABILITIES
Accounts payable and accrued liabilities         $    183,052      $    112,481
Loans payable                                       2,502,106         1,434,046
Other Liabilities                                     667,123           106,440
Deferred Taxes                                      8,531,081         6,373,701
                                                 ------------      ------------
Total  Liabilities                                 11,883,362         8,026,668

STOCKHOLDERS' EQUITY
Common stock, $.01 par value
Authorized - 10,000,000 shares
Issued - 5,309,750 shares
Outstanding - 4,639,026 and 4,656,784
 shares, respectively                                  53,097            53,097
Additional paid in capital                          9,801,548         9,798,232
Unrealized holding gains on
available-for-sale securities, net of tax          16,560,334        12,372,477
Retained earnings                                  15,169,967        16,246,156
Treasury stock, at cost, 670,724 and 652,966
 shares, respectively                              (5,167,776)       (4,923,065)
                                                 ------------      ------------
Total Stockholders' Equity                         36,417,170        33,546,897
                                                 ------------      ------------

Total Liabilities and Stockholders' Equity       $ 48,300,532      $ 41,573,565
                                                 ============      ============
</TABLE>

See accompanying notes to consolidated financial statements

<PAGE>

DAXOR CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>
                                                                Year Ended December 31,
                                                                -----------------------
                                                         2003             2002             2001
                                                     -----------      -----------      -----------
Revenues:
--------------------------------------------------------------------------------------------------
<S>                                                  <C>              <C>              <C>
Operating revenues                                   $ 1,013,647      $   767,608      $   591,692
                                                     -----------      -----------      -----------
--------------------------------------------------------------------------------------------------
Costs and expenses:
--------------------------------------------------------------------------------------------------
Operations of laboratories & costs of production       1,489,264          805,985          814,657
Selling, general, and administrative                   2,669,229        2,050,546        1,482,438
                                                     -----------      -----------      -----------
Total costs and expenses                               4,158,493        2,856,531        2,297,095
                                                     -----------      -----------      -----------

Loss from operations                                  (3,144,846)      (2,088,923)      (1,705,403)

Other income (expense):
Dividend income                                        1,897,669        1,858,025        1,860,289
Gain on sale of securities                               238,550           40,610           97,719
Other revenues                                            15,571           35,694          166,676
Interest expense, net                                    (83,133)         (39,257)        (119,926)
                                                     -----------      -----------      -----------
Total other income                                     2,068,657        1,895,072        2,004,758
                                                     -----------      -----------      -----------

Net income/( loss)  before Income Taxes               (1,076,189)        (193,851)         299,355
Provision for income taxes                                     0                0                0
                                                     -----------      -----------      -----------
Net income (loss)                                    $(1,076,189)     $  (193,851)     $   299,355
                                                     ===========      ===========      ===========

Weighted Average Number of Shares Outstanding          4,645,700        4,662,947        4,664,909
                                                     -----------      -----------      -----------

Net income (loss) per share                          $     (0.23)     $     (0.04)     $      0.06
                                                     ===========      ===========      ===========
</TABLE>

See accompanying notes to consolidated financial statements

<PAGE>

================================================================================

DAXOR CORPORATION
STATEMENTS OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME

<TABLE>
<CAPTION>
                               -------------------                                            -----------------------
                                   Common Stock                                                    Treasury Stock
                               -------------------   Additional   Accumulated                 -----------------------
                                 Number               Paid In    Comprehensive     Retained     Number
                               of Shares   Amount     Capital       Income        Earnings    of Shares     Amount         Total
                               ----------------------------------------------------------------------------------------------------
<S>                            <C>         <C>      <C>          <C>            <C>                <C>   <C>           <C>
Balances, December 31, 2000    4,663,909   $53,097  $ 9,798,232  $ 17,493,387   $ 16,140,652             $(4,813,530)  $ 38,671,838

Change in unrealized gain on
securities, net of taxes                                           (3,642,226)                                           (3,642,226)

Net income                                                                           299,355                                299,355
                               ----------------------------------------------------------------------------------------------------

Balances, December 31, 2001    4,663,909    53,097    9,798,232    13,851,161     16,440,007              (4,813,530)    35,328,967

Change in unrealized gain on
securities, net of taxes                                           (1,478,684)                                           (1,478,684)

Net loss                                                                            (193,851)                              (193,851)

Purchase of tresury stock         (7,125)                                                                   (109,535)      (109,535)
                               ----------------------------------------------------------------------------------------------------

Balances, December 31, 2002    4,656,784    53,097    9,798,232    12,372,477     16,246,156       --     (4,923,065)    33,546,897

Change in unrealized gain on
securities, net of taxes                                            4,187,857                                             4,187,857

Net loss                                                                          (1,076,189)                            (1,076,189)

Sale of treasury stock             2,142                  3,316                                               27,420         30,736

Purchase of tresury stock        (19,900)                                                                   (272,131)      (272,131)
                               ----------------------------------------------------------------------------------------------------

Balances, December 31, 2003    4,639,026   $53,097  $ 9,801,548  $ 16,560,334   $ 15,169,967        0    $(5,167,776)  $ 36,417,170
                               ====================================================================================================
</TABLE>

See accompanying notes to consolidated financial statements

<PAGE>

DAXOR CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                   Year ended December 31,

                                                            2003             2002             2001
                                                        -----------      -----------      -----------
<S>                                                     <C>              <C>              <C>
Cash flows from operating activities:
Net income or (loss)                                    $(1,076,189)     $  (193,851)     $   299,355
                                                        -----------      -----------      -----------
Adjustments to reconcile net income
 to net cash provided by operating activities:
Depreciation and amortization                                47,189           54,453           57,735
(Gain) loss on sale of investments                         (238,550)         (40,610)         (97,719)
(Gain) loss on sale of equipment                                 --           (2,750)              --
 Change in assets and liabilities:
(Increase) decrease in accounts receivable                   74,971          (37,737)         (66,315)
(Increase) decrease in inventory                              3,040          (48,477)          31,252
(Increase) decrease in other current assets                 (26,527)          (4,126)          20,196
(Increase) decrease in other assets
   net of amortization                                           --             (300)         (33,900)
Increase in accounts payable, accrued
expenses and other liabilities net of "short sales"          66,471           60,626           11,024
                                                        -----------      -----------      -----------
Total adjustments                                           (28,406)         (18,921)         (77,727)
                                                        -----------      -----------      -----------

Net cash provided by (used in)operating activities       (1,149,595)        (212,772)         221,628
                                                        -----------      -----------      -----------

Cash flows from investing activities:
Purchase of property and equipment                          (54,354)        (114,879)         (10,994)
Proceeds from sale of equipment, net                         45,000            2,750               --
Purchases of securities, net of sales                      (340,893)        (517,207)         962,111
Net proceeds from (repayments of) loans from
brokers used to purchase securities                         868,060          734,046         (775,363)
Proceeds from "short sales" not closed                      663,466           98,683           16,128
                                                        -----------      -----------      -----------

Net cash provided by investing activities                 1,181,279          203,393          191,882
                                                        -----------      -----------      -----------

Cash flows from financing activities:
Proceeds from (repayment of) bank loan                      200,000         (300,000)              --
Proceeds from sale of treasury stock                         30,736
Purchase of treasury stock                                 (272,131)        (109,535)              --
                                                        -----------      -----------      -----------

Net cash used in financing activities                       (41,395)        (409,535)              --
                                                        -----------      -----------      -----------
Net increase (decrease) in cash and
  cash equivalents                                           (9,711)        (418,914)         413,510

Cash and cash equivalents at beginning of year               13,035          431,949           18,439
                                                        -----------      -----------      -----------

Cash and cash equivalents at end of year                $     3,324      $    13,035      $   431,949
                                                        ===========      ===========      ===========

Non-cash investing activities:
Unrealized gain (loss) on securities, net
  Of deferred taxes                                     $ 4,187,857      $(1,478,684)     $(3,642,226)
                                                        ===========      ===========      ===========

Supplemental cash flow disclosure:
Interest paid                                           $    86,675      $    40,533      $   120,373
                                                        ===========      ===========      ===========
</TABLE>

See accompanying notes to consolidated financial statements

<PAGE>

                                DAXOR CORPORATION
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1) BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

Business

      Daxor Corporation is a medical device manufacturing company that offers
additional biotech services, such as cryobanking, through its wholly owned
subsidiary Scientific Medical Systems Corp. The main focus of Daxor Corporation
has been the development of an instrument that rapidly and accurately measures
human blood volume. This instrument is used in conjunction with a single use
diagnostic injection and collection kit.

Significant Accounting Policies

Principles of Consolidation

      The consolidated financial statements include the accounts of Daxor
Corporation and Scientific Medical Systems Corp, a wholly-owned subsidiary. All
significant inter-company transactions and balances have been eliminated in
consolidation.

Use of Estimates

      The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosures of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.

Segment Information

      The Company has one operating segment comprised of the sale of blood
analysis equipment and related biotech services. The Company's business is
currently conducted in the United States.

Cash and Cash Equivalents

      The Company considers cash equivalents to be all highly liquid investments
purchased with an original maturity of 90 days or less.

Fair Value of Financial Instruments

      Carrying amounts of certain financial instruments of the Company,
including cash and cash equivalents, accounts receivable and payable, and
accrued expenses approximate fair value because of their short maturities.

Available-for-Sale Securities

      Available-for-sale securities represent investments in debt and equity
securities (primarily common and preferred stock of utility companies)that
management has determined meet the definition of available-for-sale under SFAS
No. 115, Accounting for Certain Investments in Debt and Equity Securities.
Accordingly, these investments are stated at fair market value and all
unrealized holding gains or losses are recorded in the Equity section of the
Balance Sheet as Comprehensive Income (Loss). Conversely, all realized gains,
losses and earnings are recorded in the Statement of Operations under Other
Income (Expense).

      Historical cost is used by the Company to determine all gains and losses,
and fair market value is obtained by readily available market quotes on all
securities.

Accounts Receivable

      Accounts receivable are deemed to be fully collectible.

Inventory

      Inventory is stated at the lower of cost or market, using the first-in,
first-out method (FIFO), and consists primarily of finished goods.

<PAGE>

Prepaid Expenses and Other Current Assets

      Prepaid expenses and other current assets generally consist of prepayments
for future services and corporate income taxes. Prepayments are expensed when
the services are received or as the prepaid income taxes are offset by the
related income tax liability. All prepaid expenses and income taxes are expensed
within one year of the Balance Sheet date and are thus classified as Current
Assets.

Property and Equipment

      Property and Equipment is stated at cost and consists of laboratory and
office equipment, furniture and fixtures, and leasehold improvements. These
assets are depreciated under the straight-line method, over their estimated
useful lives, which range from 5 to 39 years.

      Amounts spent to repair or maintain these assets arising out of the normal
course of business are expensed in the period incurred. The cost of betterments
and additions are capitalized and depreciated over the life of the asset. The
cost of assets disposed of or determined to be non-revenue producing, together
with the related accumulated depreciation applicable thereto, are eliminated
from the accounts, and any gain or loss is recognized.

      In accordance with SFAS No. 144, Accounting for the Impairment or Disposal
of Long-Lived Assets, management reviews long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. Currently, there is no impairment of any
long-lived assets.

Income Taxes

      The Company accounts for income taxes under the provisions of SFAS No.
109, Accounting for Income Taxes. This pronouncement requires recognition of
deferred tax assets and liabilities for the estimated future tax consequences of
event attributable to differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax bases and
operating loss and tax credit carry forwards. Deferred tax assets and
liabilities are measured using enacted tax rates in effect for the year in which
the differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of changes in tax rates is recognized in the
statement of operations in the period in which the enactment rate changes.
Deferred tax assets and liabilities are reduced through the establishment of a
valuation allowance at such time as, based on available evidence, it is more
likely than not that the deferred tax assets will not be realized.

Comprehensive Income

      The Company reports components of comprehensive income under the
requirements of SFAS No. 130, Reporting Comprehensive Income. This statement
establishes rules for the reporting of comprehensive income and requires certain
transactions to be presented as separate components of stockholders' equity. The
Company currently reports the unrealized holding gains and losses, net of
deferred taxes, as comprehensive income.

Stock Options

      The Company applies the intrinsic-value-based method of accounting
prescribed by Accounting Principles Board, or APB, Opinion No. 25, Accounting
for Stock Issued to Employees, and related interpretations including Financial
Accounting Standards Board, or FASB, Interpretation No. 44, Accounting for
Certain Transactions involving Stock Compensation, an Interpretation of APB
Opinion No. 25, issued in March 2000, to account for its stock options. Under
this method, compensation expense is recorded on the date of the grant only if
the current market price of the underlying stock exceeded the exercise price.
SFAS No. 123, Accounting for Stock Based Compensation, established accounting
and disclosure requirements

<PAGE>

using a fair-value-based method of accounting for stock-based employee
compensation plans. As allowed by SFAS No. 123, the Company has elected to
continue to apply the intrinsic-value-based method of accounting described
above, and has adopted only the disclosure requirements of SFAS No. 123. The
following table illustrates the effect on the net loss if the fair-value-based
method has been applied to all outstanding and unvested awards in each period.

<TABLE>
<CAPTION>
                                                    2003             2002           2001
                                                 -----------      ---------      ---------
<S>                                              <C>              <C>            <C>
      Net income (loss), as reported             $(1,076,189)     $(193,851)     $ 299,355
      Deduct total stock-based employee
      compensation expense determined
      under fair-value-based method, net
      of tax                                         (21,551)       (18,723)        (4,079)
                                                 -----------      ---------      ---------
      Proforma net income (loss)                 $(1,097,740)     $(212,574)     $ 295,276
                                                 ===========      =========      =========

      Pro forma net income (loss) per share:
      Basic and diluted                          $      (.24)     $    (.05)     $     .06
                                                 ===========      =========      =========
</TABLE>

<PAGE>

      No stock options were granted to employees in 2003. The weighted-average
fair value per stock option granted in 2002 and 2001 was $4.61 and $5.10,
respectively. The fair value of each option grant is estimated on the date of
grant using the Black-Scholes option-pricing model with the following
weighted-average assumptions used for grants in 2002 and 2001: no dividend
yield, expected volatility of 40.96% and 42.75%, respectively, risk-free
interest rates of 2.13% and 3.52%, respectively and an expected life of 3 years
for all years.

Research and Development

      Costs associated with the development of new products are charged to
operations as incurred.

Advertising Costs

      Advertising expenditures relating to the advertising and marketing of the
Company's products and services are expensed in the period incurred.

Earnings Per Share

      The Company computes earnings per share in accordance with SFAS No. 128,
Earnings Per Share. Basic earnings per share is computed by dividing income or
loss by available to common stockholders by the weighted average number of
common shares outstanding.

Leased Employees

      The Company has entered into an agreement with ADP TotalSource, whereby
the Company leases its employee base from ADP. The agreement requires the
Company to reimburse ADP for all employee wages, related taxes, employee benefit
costs and human resource fees.

      The Company records these payments as the same classifications for which
the reimbursement is made. (i.e. Wage reimbursements are recorded as wage
expense.)

Future Accounting Requirements

      In December 2004, the FASB revised SFAS No. 123 (FAS 123R), Share-Based
Payment, which requires companies to expense the estimated fair value of
employee stock options and similar awards. The accounting provisions of FAS 123R
will be effective for the third quarter of fiscal 2005.

      The Company will adopt the provisions of FAS 123R using a modified
prospective application. Under modified prospective application, FAS 123R, which
provides certain changes to the method for valuing stock-based compensation
among other changes, will apply to new awards and to awards that are outstanding
on the effective date and are subsequently modified or cancelled. Further
compensation expense for outstanding awards for which the requisite service had
not been rendered as of the effective date will be recognized over the remaining
service period using the compensation cost calculated for pro forma disclosure
purposes under FAS 123. The Company is in the process of determining how the new
method of valuing stock-based compensation as prescribed in FAS 123R will be
applied to valuing stock-based awards granted after the effective date and the
impact the recognition of compensation expense related to such awards will have
on its consolidated financial statements.

      In November 2004, the FASB issued SFAS No. 151, Inventory Costs, an
amendment of ARB No. 43, Chapter 4. This Statement is meant to eliminate any
differences existing between the FASB standards and the standards issued by the
International Accounting Standards Board by clarifying that any abnormal idle
facility expense, freight, handling costs and spoilage be recognized as
current-period charges. This Statement is required to be adopted in the first
quarter of 2006; however, early application is permitted. The Company does not
expect the adoption of this Statement to have a material impact on results of
operations, financial position or cash flows.

      In December 2003, the FASB revised FIN No. 46 (FIN 46R), Consolidation of
Variable Interest Entities, an interpretation of ARB No. 51., which requires
entities with non-similar operations to consolidate if certain factors are
present. The accounting provisions of FIN 46R became effective for periods
ending after December 15, 2003. This Interpretation did not have any impact on
results of operations, financial position or cash flows of Daxor Corporation.

<PAGE>

Reclassifications

      Certain reclassifications have been made to the Company's 2002 and 2001
consolidated financial statements to conform to the current period
presentations. Revenues, as previously presented, included dividend income,
gains on the sale of securities, and miscellaneous income. For purposes of this
financial statement presentation, these components of income have been
reclassified as Other income.

(2) AVAILABLE-FOR-SALE SECURITIES

      Upon adoption of SFAS No. 115, Accounting for Certain Investments in Debt
and Equity Securities, management has determined that the company's portfolio is
best characterized as "Available-For-Sale". SFAS No. 115 requires these
securities to be recorded at their fair market values, with the offsetting
unrealized holding gains or losses being recorded as Comprehensive Income
(Loss)in the Equity section of the Balance Sheet. The adoption of this
pronouncement has resulted in an increase in the carrying value of the company's
available-for-sale securities, as at December 31, 2003 and December 31, 2002, of
approximately 112.48% and 85.89%,respectively, over its historical cost.

      In accordance with the provisions of SFAS No. 115, the adjustment in
stockholders' equity has been made net of the tax effect had these gains been
realized.

      The Company uses the historical cost method in the determination of its
realized and unrealized gains and losses. The following tables summarize the
Company's investments as of:

                                December 31, 2003

Type of                                         Unrealized          Unrealized
security          Cost          Fair Value     holding gains      holding losses
--------          ----          ----------     -------------      --------------

Equity        $22,271,842      $47,368,871      $25,407,422        $   310,393
Debt               35,902           30,288            2,170              7,784
              ----------------------------------------------------------------

Total         $22,307,744      $47,399,159      $25,409,592            318,177
              ===========      ===========      ===========        ===========

                                December 31, 2002

Type of                                         Unrealized          Unrealized
security          Cost          Fair Value     holding gains      holding losses
--------          ----          ----------     -------------      --------------

Equity        $21,796,315      $40,547,587      $19,960,514        $ 1,209,242
Debt               30,669           25,575            8,865             13,959
              ----------------------------------------------------------------

Total         $21,826,984      $40,573,162      $19,969,379        $ 1,223,201
              ===========      ===========      ===========        ===========

      At December 31, 2003, the securities held by the Company had a market
value of $47,399,159 and a cost basis of $22,307,744 resulting in a net
unrealized gain of $25,091,415 or 112.48% of cost. Debt securities, which
consist of Bonds, are scheduled to mature in April 2006 and May 2008.

      At December 31, 2002, the securities held by the Company had a market
value of $40,573,162 and a cost basis of $21,826,984 resulting in a net
unrealized gain of $18,746,178 or 85.89% of cost.

      At December 31, 2003 and December 31, 2002 marketable securities,
primarily consisting of preferred and common stocks of utility companies, and
are valued at fair value.

(3) Property and Equipment

      Property and equipment as at December 31, 2003 and 2002, respectively,
consist of:

                                                  2003                 2002
Machinery and equipment                        $   727,689          $   731,260
Furniture and fixtures                             325,635              317,710
Leasehold improvements                             295,530              295,530
                                               -----------          -----------
                                                 1,348,854            1,344,500
Accumulated depreciation                        (1,045,481)          (1,005,625)
                                               -----------          -----------
Property and equipment, net                    $   303,373          $   338,875
                                               ===========          ===========

For the years ended December 31, 2003, 2002 and 2001, depreciation expense for
the above listed assets was $44,856, $52,120 and $56,179, respectively.

<PAGE>

(4) Other Assets

      Included in Other Assets is an intangible asset (Customer List) that is
being amortized over its estimated useful life of 15 years. The asset was
recorded at its original cost of $35,000 and has accumulated amortization of
$6,222 and $3,889 at December 31, 2003 and 2002, respectively. Amortization
expense was $2,333 for the years ended December 31, 2003 and 2002.

      In accordance with SFAS No. 142, Goodwill and Other Intangible Assets,
management periodically reviews the asset's value for potential impairment.

      As at December 31, 2003 and 2002, management does not believe that the
value of this asset has been impaired.

(5) Loans Payable

      As at December 31, 2003 and December 31, 2002, the Company has a note
payable of $900,000 and $700,000, respectively, with a bank. The note matures
each year, with an option to renew, and is classified as short term. The note
balance is an aggregate of borrowings (loans) that renews as one note each year,
but is subject to different interest rates depending on the individual amount of
each borrowing. The loans bears interest at approximately 3.0% at December 31,
2003 and 2002, respectively. These loans are secured by certain marketable
securities of the Company.

      Short-term margin debt owed to various brokers, secured by the Company's
marketable securities , totaled $1,602,106 at December 31, 2003 and $734,046 at
December 31,

2002.

SHORT-TERM BORROWINGS
Years Ended December 31, 2003, 2002, 2001

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------
Column A                Column B           Column C        Column D         Column E           Column F
--------                --------           --------        --------         --------           --------
---------------------------------------------------------------------------------------------------------
                                         Weighted
                                         average         Maximum           Average           Weighted
Category of                              interest        amount            amount            average
aggregate              Balance at        rate at end     outstanding       outstanding       interest
short-term             the end of        of the          during this       during the        rates during
borrowings             period            period          period            period            the period
---------------------------------------------------------------------------------------------------------
<S>                    <C>                  <C>           <C>               <C>                  <C>
2003
---------------------------------------------------------------------------------------------------------
Banks                     900,00            3.00%           900,000           883,333            3.00%
---------------------------------------------------------------------------------------------------------
Brokers                1,806,214            3.12%         2,345,940         1,360,120            3.88%
---------------------------------------------------------------------------------------------------------
All Categories         2,706,214            3.08%         3,245,940         2,243,134            3.56%
---------------------------------------------------------------------------------------------------------
2002
---------------------------------------------------------------------------------------------------------
Banks                    700,000            4.12%         1,000,000           725,000            4.07%
---------------------------------------------------------------------------------------------------------
Brokers                  734,046            4.05%           734,046           568,725            4.15%
---------------------------------------------------------------------------------------------------------
All Categories         1,434,046            4.08%         1,734,046         1,293,725            4.13%
---------------------------------------------------------------------------------------------------------
2001
---------------------------------------------------------------------------------------------------------
Banks                  1,000,000             5.7%         1,000,000         1,000,000            6.95%
---------------------------------------------------------------------------------------------------------
Brokers                        0            6.12%         1,054,607           678,343            6.01%
---------------------------------------------------------------------------------------------------------
All Categories         1,000,000            5.91%         2,054,607         1,678,343            6.54%
---------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

The average borrowings were determined on the basis of the amounts outstanding
at each month-end. The weighted interest rate during the year was computed by
dividing actual interest expense in each year by average short-term borrowings
in such year.

(6) Other Liabilities

      At December 31, 2003 and December 31, 2002, the Company also maintained a
short position in certain marketable securities. These positions were sold for
$663,466 at December 31, 2003, and $98,683 at December 31, 2002, and had
respective market values of $547,595 and $71,775 resulting in unrealized gains
of $ 115,871 at December 31, 2003 and $26,908 at December 31, 2002.

(7) Stock Options

      The Company, through no formal Stock Option Plan, has issued options to
purchase shares of common stock to various employees. All issuances were
approved by the Board of Directors, and have various vesting schedules. As at
December 31, 2003, none of the outstanding options were exercisable.

                  Details of the option activity is as follows:

                                                                        Weighted
                                                                        Average
                                                        Number of       Exercise
                                                          Shares          Price
                                                         --------       --------

Outstanding, December 31, 2000                              4,000        $10.0 0

  Granted                                                  15,600          17.67

  Exercised                                                    --             --

  Cancelled                                                    --             --
                                                         --------       --------

Outstanding, December 31, 2001                             19,600       $  16.10

  Granted                                                 102,000          15.25

  Exercised                                                    --             --

  Cancelled                                               (61,800)         15.27
                                                         --------       --------

Outstanding, December 31, 2002                             59,800       $  15.51

  Granted                                                      --             --

  Exercised                                                (1,000)         10.00

  Cancelled                                               (21,000)         15.33
                                                         --------       --------

Outstanding, December 31, 2003                             37,800       $  15.76
                                                         ========       ========

<PAGE>

<TABLE>
<CAPTION>
         Options Outstanding                                    Options Exercisable
---------------------------------------      -------------------------------------------------------
                                              Weighted-
                              Number           Average       Weighted-       Number        Weighted-
                          Outstanding at      Remaining      Average      Exercisable       Average
         Range of          December 31,      Contractual     Exercise     December 31,      Exercise
     Exercise Prices           2003             Life           Price          2004           Price
------------------------   ------------      -----------     ---------    ------------     ---------
<S>                           <C>             <C>            <C>                   <C>     <C>
       $8.00 - $10.00          3,000          1.7 years      $   10.00             --      $      --

      $14.00 - $18.00         34,800          3.4 years      $   16.26             --      $      --
                              ------                         ---------
                              37,800          3.3 years      $   15.76             --      $      --
                              ======                         =========
</TABLE>

In addition to the employee options described above, the Company issued 25,000
options to a consultant on March 1, 2002 at an exercise price of $21.00. These
options expire on March 1, 2005.

(7) Current Income Taxes

      The following is a reconciliation of the federal statutory tax rate of 34%
for 2003, 2002 and 2001, with the provision for income taxes:

                                                    2003       2002       2001
                                                    ----       ----       ----

Statutory tax rate                                   (34)%      (34)%      (34)%
Tax benefit of NOL                                                          34%
State and city taxes
Loss not subject to taxation                          34%        34%
                                                    ----       ----       ----
Provision for income taxes                             0          0          0
                                                    ----       ----       ----
Effective federal tax rate                             0%         0%         0%
                                                    ----       ----       ----

      The Company, due to current losses and loss carry forwards from previous
years, has not accrued or paid taxes based on income. It has, however, paid
State and City taxes which were assessed on its Capital Base. In accordance with
SFAS No. 109, Accounting for Income Taxes, these Capital Base assessments were
not classified as income taxes.

<PAGE>

(8) Deferred Income Taxes

      Deferred income taxes result from differences in the recognition of gains
and losses on marketable securities, as well as operating loss carry forwards,
for tax and financial statement purposes. The deferred income tax results in a
liability for the marketable securities, while the operating loss carry forwards
result in a deferred tax asset.

      A valuation allowance has been recorded for the entire deferred tax asset
as a result of uncertainties regarding the realization of the asset balance due
to the history of losses and the variability of operating results.

      The deferred tax liability that results from the marketable securities
does not flow through the Statement of Operations due to the classification of
the marketable securities as available-for-sale. Instead, the deferred tax
liability is recorded against the Comprehensive income, in the Equity section.

      The deferred tax computations, computed at federal statutory rates of 34%,
are as follows:

                                                     2003               2002
Deferred tax assets:
Net operating loss carry forwards                $ 4,278,848        $ 3,468,273
Valuation allowance                               (4,278,848)        (3,468,273)
                                                 -----------        -----------
Total deferred tax assets                                  0                  0
                                                 ===========        ===========

Deferred tax liabilities:
Fair market value adjustment
for available-for-sale securities                $ 8,531,081        $ 6,373,701
                                                 ===========        ===========

(9) Concentrations of Credit Risk

      Financial instruments which potentially subject the Company to
concentrations of credit risk consist primarily of marketable securities. The
Company maintains its investments in four difference brokerage accounts, all of
which are insured by Securities Investor Protection Corporation (SIPC). The
limits of this insurance are up to $100,000 for the total amount of cash on
deposit with each Broker, and up to $500,000 for the total amount of securities
held by each Broker. Each of these brokerage houses is well known in the
industry and management does not believe that these securities bear any risk of
loss over and above the basic risk that a security bears through the normal
activity of the securities markets. However, as at December 31, 2003, the fair
market value of securities in excess of the SIPC insured limit is $45,884,624,
while there is no cash on deposit in excess of the insured limit.

<PAGE>

(10) Related Party Transactions

      The Company subleases a portion of its New York City office space to the
President of the Company. This sublease agreement has no formal terms and is
executed on a month to month basis. The annual amount of rental income received
in each the years ended December 31, 2003, 2002 and 2001 was $9,600.

(11) Research and Development Expenses

      Research and development expenses were $348,265, $330,000, and $325,745
for 2003, 2002, and 2001 respectively. All research and development costs are
expensed in the period they are incurred.

(12) Interest Expense and Income

      Interest expense was $86,675, $40,532, and $120,373 and interest income
was $3,542, $1,275 and $447 in 2003, 2002 and 2001 respectively.

(13) Commitments and Contingencies

      (A) Operating Leases

      The Company leases office and laboratory space in both New York City and
Tennessee. The lease agreement for the New York City facility is a
non-cancelable lease and will expire on December 31, 2015. The Tennessee
facility is currently leased on a month-to-month basis.

      The Company subleases space in its New York facility to a related party
and a third party. Both subtenants lease on a month to month basis with no
formal agreement. The amount of rental income received for the years ended
December 31, 2003, 2002 and 2001 was $15,571 and is classified as other income
in the Statement of Operations.

      Future minimum rental payments under the non-cancelable operating lease,
exclusive of cost of living and tax escalation increases, are as follows:

                         2004        $  182,340
                         2005        $  182,340
                         2006        $  182,340
                         2007        $  182,340
                         2008        $  182,340
                   Thereafter        $1,276,380

      Rent expense for all non-cancelable operating leases was $281,506,
$239,543 and $386,248 for the years ended December 31, 2003, 2002 and 2001
respectively.

      B) Contingent Liabilities

      The Company has pending several claims incurred in the normal course of
business, which, in the opinion of management, based on the advice of outside
legal counsel, will not have a material effect on the financial statements.

(14) Subsequent Events (Unaudited)

      Effective July 6, 2004, the Company instituted the Daxor Corporation 2004
Stock Option Plan. This Plan was created to provide incentive to employees,
officers, agents, consultants and independent contractors of the Company by
offering proprietary interest in the Company.

      The Company was involved in a dispute with its landlord in New York City.
This dispute arose out of a rental rate dispute. In February 2005, the dispute
was settled and the Company voluntarily agreed to pay the landlord approximately
$45,000 in additional rent. This $45,000 liability was accrued for the purposes
of this financial statement presentation and is listed in Accrued Expenses.

(15) Selected Financial Data (Unaudited)

Selected Quarterly Financial Data

<TABLE>
<CAPTION>
                                                                     Quarter Ended
                                               ----------------------------------------------------------

                                                March 31        June 30         Sept 30       December 31
                                               ----------------------------------------------------------
<S>                                            <C>             <C>             <C>             <C>
2003
           Total operating revenues            $ 218,683       $ 290,411       $ 301,816       $ 202,737
           Total revenue and other income      $ 737,617       $ 771,667       $ 904,183       $ 751,970
           Gross profit (loss)                 $(779,012)      $(709,835)      $(757,396)      $(898,603)
           Net income (loss)                   $(274,585)      $(247,654)      $(180,041)      $(373,909)
           Net income (loss) per share         $    (.06)           (.05)      $    (.04)      $    (.08)

2002
           Total operating revenues            $ 193,063       $ 196,441       $ 200,100       $ 178,004
           Total revenue and other income      $ 661,838       $ 753,088       $ 794,270       $ 492,741
           Gross profit (loss)                 $(424,629)      $(471,335)      $(481,686)      $(711,273)
           Net income (loss)                   $  32,574       $  78,091       $ 105,009       $(409,525)
           Net income (loss) per share         $     .01       $     .01       $     .03       $    (.09)
</TABLE>

Certain reclassifications have been made to the Company's 2002 consolidated
financial statements to conform to the current period presentations.

<PAGE>

Item 9. Changes and Disagreements with Accountants on Accounting and Financial
        Disclosure

There were no changes in and disagreements with accountants on accounting and
financial disclosures.

Item 9A. Controls and Procedures

Within the 90 days prior to the date of this report, the Company carried out an
evaluation, under the supervision and with the participation of the Company's
management, including the Company's Chief Executive Officer and Chief Financial
Officer of the effectiveness of the design and operation of the Company's
disclosure controls and procedures pursuant to Rule 13a-14 under the Securities
and Exchange of 1934, as amended. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded the Company's disclosure
controls and procedures are effective in timely alerting them to material
information relating to the Company required to be included in the Company's
periodic SEC filings.

There have been no significant changes in the Company's internal controls or in
other factors, which could significantly affect internal controls subsequent to
the date the Company carried out its evaluation.

Part III.

Item 10. Directors and Executive Officers of the Registrant

The information required by item 10 is incorporated by reference to our proxy
statement for our 2004 Annual Meeting of Shareholders, which was filed with the
Securities and Exchange Commission within 120 days after the close of our 2003
year end.

Item 11. Executive Compensation

The information required by item 11 is incorporated by reference to our proxy
statement for our 2004 Annual Meeting of Shareholders, which was filed with the
Securities and Exchange Commission within 120 days after the close of our 2003
year end.

Item 12. Security Ownership of Certain Beneficial Owners and Management Related
         Shareholder Matters

This information required by item 12 is incorporated by reference to our proxy
statement for our 2004 Annual Meeting of Shareholders, which was filed with the
Securities and Exchange Commission within 120 days after the close of our 2003
year end.

Item 13. Certain Relationships and Related Transactions

There are no relationships or related transactions beyond those which have been
disclosed in the 10-K.

Item 14. Principal Accountant Fees and Services

The information required by item 14 is incorporated by reference to our proxy
statement for our 2004 Annual Meeting of Shareholders, which was filed with the
Securities and Exchange Commission within 120 days after the close of our 2003
year end.


                                       18
<PAGE>

Part IV

Item 15. Exhibits, Financial Statement Schedule and Reports on Form 8-K

(a)(1) LIST OF FINANCIAL STATEMENTS

The following financial statements are included herein under Part II, Item 8,
Consolidated Financial Statements:

o     Report of Independent Registered Public Accounting Firm

o     Report of Independent Auditors

o     Consolidated Balance Sheets - December 31, 2003 and 2002

o     Consolidated Statements of Operations for the years ended December 31,
      2003, 2002, and 2001

o     Consolidated Statements of Stockholder's Equity and Comprehensive Income
      for the years ended December 31, 2003, 2002 and 2001.

o     Consolidated Statement of Cash Flows for the years ended December 31,
      2003, 2002 and 2001

o     Notes to Consolidated Financial Statements

(3) LIST OF EXHIBITS

Description of Exhibits

31.1  Certification by Principal Executive Officer Pursuant to Securities
      Exchange Act Rule 13a-14

31.2  Certification of Principal Accounting Officer Pursuant to Securities
      Exchange Act Rule 13a-14

32.1  Certification by Joseph Feldschuh, MD pursuant to 18 U.S.C. Section 1350,
      as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2  Certification by Stephen Feldschuh pursuant to 18 U.S.C. Section 1350, as
      Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(b) Reports on Form 8-K

There were no Reports on Form 8-K.


                                       19
<PAGE>

                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities and
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereto duly authorized.

                                DAXOR CORPORATION


                            by: /s/ Joseph Feldschuh
                            ------------------------
                              Joseph Feldschuh, M.D
                             President and Principal
                                Executive Officer
                              Chairman of the Board

Dated: April 15, 2005

Pursuant to the requirements of the Securities and Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.

Signature                                   Title                 Date
---------                                   -----                 ----


/s/ Joseph Feldschuh           President and Director             April 15, 2005
--------------------------     Principal Executive Officer
Joseph Feldschuh, M.D.


/s/ Stephen Feldschuh          Vice President of Operations       April 15, 2005
--------------------------     & Principal Accounting Officer
Stephen Feldschuh


/s/ Gary Fischman, PhD         Vice President                     April 15, 2005
--------------------------
Gary Fischman, PhD


/s/ Liliya Morgaylo            Corporate Treasurer                April 15, 2005
--------------------------
Liliya Morgaylo


/s/ Diane M. Meegan            Corporate Secretary                April 15, 2005
--------------------------
Diane M. Meegan


/s/ Robert Willens             Director                           April 15, 2005
--------------------------
Robert Willens


/s/ James Lombard              Director                           April 15, 2005
--------------------------
James Lombard


/s/ Martin Wolpoff             Director                           April 15, 2005
--------------------------
Martin Wolpoff


/s/ Bruce Slovin               Director                           April 15, 2005
--------------------------
Bruce Slovin

Board of Directors:

Name                           Title
Dr. Joseph Feldschuh           Chairman, President, & CEO
James Lombard                  Director
Martin Wolpoff                 Director
Robert Willens                 Director
Bruce Slovin                   Director


                                       20